RedHill Biopharma
8045 Arco Corporate Drive
Suite 200
Raleigh
NC
27617
United States
Website: http://www.redhillbio.com/
477 articles about RedHill Biopharma
-
RedHill's Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension
12/5/2022
RedHill Biopharma Ltd. today announced that the U.S. Food and Drug Administration's (FDA) Exclusivity Board has granted Aemcolo®2 five years' exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, in addition to the five years' data exclusivity granted as a new chemical entity (NCE) for the treatment of travelers' diarrhea (TD) caused by non-invasive strains of Escherichia coli (E. coli) in adults.
-
RedHill Biopharma Prices $8.0 Million Underwritten Public Offering
12/2/2022
RedHill Biopharma Ltd. today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $8.0 million.
-
RedHill Biopharma Announces Proposed Public Offering - December 01, 2022
12/1/2022
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it intends to offer and sell, subject to market and other conditions American Depositary Shares and warrants to purchase ADSs in an underwritten public offering.
-
RedHill Biopharma Announces Q3/22 Results and Operational Highlights
11/29/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its third quarter 2022 financial results and operational highlights.
-
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
11/17/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive in vivo results from a new pre-clinical study evaluating the effects of opaganib[1] on radiation-induced hematologic and renal toxicity, undertaken by RedHill and its partner Apogee Biotechnology Corporation ("Apogee").
-
RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik®
11/14/2022
RedHill Biopharma Ltd. announced that it has reached a non-binding agreement in principle with HCR Collateral Management, LLC with respect to the terms of a transfer of RedHill's rights in Movantik® to HCR in exchange for the extinguishment of all RedHill's obligations under the Credit Agreement between RedHill's U.S. subsidiary RedHill Biopharma Inc. and HCR dated as of February 23, 2020.
-
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
11/14/2022
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced acceleration of opaganib's development program for protection against radiation injury and cancer radiotherapy.
-
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
11/7/2022
RedHill Biopharma Ltd., a specialty biopharmaceutical company, reported its second quarter 2022 financial results and operational highlights, restatement of first quarter 2022 financial results and the provision of third quarter 2022 estimates.
-
RedHill Presents New Talicia® Data Analyses at Obesity Week 2022
11/4/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the presentation of new Talicia® data analyses for the treatment of H. pylori, at the Obesity Week Annual Meeting, November 1-4, 2022.
-
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment Patent
10/19/2022
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the granting by the United States Patent and Trademark Office (USPTO) of a further method of use patent that protects the administration of opaganib.
-
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
10/18/2022
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency.
-
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
10/3/2022
RedHill Biopharma Ltd. announced study results showing in vitro efficacy against the currently dominant Omicron COVID-19 sub-variant BA.5, by both of RedHill's novel, oral, host-directed and broad-acting investigational antivirals, once-daily RHB-107 1 and twice-daily opaganib2.
-
RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM Infections
8/17/2022
RedHill Biopharma today announced that the European Commission has granted Orphan Drug Designation to RHB-2041 for the treatment of nontuberculous mycobacteria (NTM) disease.
-
RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
7/12/2022
RedHill invited to give prestigious oral presentation of important data detailing high eradication rates across body mass index (BMI) groups with Talicia, the U.S.'s leading brand for Helicobacter pylori (H. pylori) eradication treatment - invitation sent to researchers with significant recently published clinical findings.
-
RedHill announced that it will lay off a third of its U.S. workforce in an effort to save money over the next year and a half.
-
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
6/23/2022
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22.
-
RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
6/17/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.
-
RedHill Presents New Talicia® Data Analyses at DDW 2022
5/25/2022
RedHill Biopharma Ltd. announced the presentation of two new data analyses from the Talicia® H. pylori eradication clinical trials program at Digestive Diseases Week 2022.
-
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
5/9/2022
RedHill Biopharma Ltd. today announced that it has entered into a definitive agreement with a single leading healthcare investor for the purchase and sale of 10,563,380 of the Company's American Depositary Shares ("ADSs").
-
RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro
4/11/2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), today announced study results in which opaganib (ABC294640)1, a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.